Alnylam Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2830 www.alnylam.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

3 Great Healthcare Stocks To Own In October 2026 - Oct 2nd, 2026 7:12 am
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM - Sep 29th, 2026 7:00 am
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Sep 28th, 2026 7:57 am
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - Sep 28th, 2026 3:43 am
RNAi drug specialist ADARx raises $446M IPO - Sep 24th, 2026 6:36 pm
Was Moderna Stock's Cancer Vaccine Run Visible In Advance? - Sep 22nd, 2026 11:39 am
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day - Sep 21st, 2026 10:40 am
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook - Sep 20th, 2026 10:02 am
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial - Sep 19th, 2026 7:01 pm
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics - Sep 18th, 2026 4:42 am
Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism? - Sep 15th, 2026 1:18 pm
Slate Medicines Names Kenneth Koblan as Chief Scientific Officer - Sep 15th, 2026 9:18 am
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics - Sep 15th, 2026 3:58 am
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture - Sep 15th, 2026 3:04 am
Alger Russell Innovation Index Updates for Third Quarter 2026 - Sep 14th, 2026 10:53 am
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined - Sep 10th, 2026 5:44 am
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy - Sep 4th, 2026 2:02 am
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue? - Sep 2nd, 2026 9:30 am
Alnylam to Webcast Presentations at Upcoming September Investor Conferences - Sep 2nd, 2026 6:00 am
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects - Sep 1st, 2026 8:56 am